Heritage Cannabis Entering the New York Recreational Market with Products Available in the State this Summer

Heritage Cannabis Entering the New York Recreational Market with Products Available in the State this Summer

Article content

media

TORONTO — Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), is thrilled to announce that it is entering the recreational cannabis market in New York, with RAD branded vape and concentrate products becoming available to New York consumers this summer.

Article content

Heritage continues to target the legal markets in the US with an asset light model and has signed a manufacturing and distribution agreement with a local partner that will primarily produce and sell products using Heritage’s innovative formulations and flavours that have achieved success in other markets. The initial launch will be 6 SKUs and Heritage plans to add additional RAD products including live resin, rosin, and infused pre-rolls, as well as expand product offerings with additional Heritage brands.

Article content

New York State legalized recreational cannabis in 2021, and recently celebrated the first legal “4/20” in the state. The New York market is projected to be valued at over $4 billion within five years according to Forbes and is expected to be second only to the California market in the U.S. and approximately the size of the Canadian legal market.

“This is an ideal time to be introducing Heritage’s recreational cannabis products to the state of New York as the official start of legalized cannabis sales begin. With strong market growth projected in New York, Heritage can capture a piece of this market with our well developed, well recognized RAD branded products,” said David Schwede, CEO of Heritage. “Our U.S. strategy continues to grow as previously communicated and we are finding capital efficient ways to do it.”

See also  EH Group tests HTPEM Fuel Cell to decarbonise aviation

About Heritage Cannabis Holdings Corp.

Heritage Cannabis is a leading cannabis company offering innovative products to both the medical and recreational legal cannabis markets in Canada and the U.S., operating under two licensed manufacturing facilities in Canada. The company has an extensive portfolio of high-quality cannabis products under the brands Purefarma, Pura Vida, RAD, Premium 5, Thrifty, Adults Only, feelgood., the CB4 suite of medical products in Canada and ArthroCBD in the U.S.

ON BEHALF OF THE BOARD OF DIRECTORS OF HERITAGE CANNABIS HOLDINGS CORP.

“David Schwede”
David Schwede, CEO

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

Forward-Looking Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

See also  Asia Markets: Asian markets gain on new hope for coronavirus vaccine

Article content

By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements.

An investment in securities of the Company is speculative and subject to several risks including, without limitation, the risks discussed under the heading “Risks and Uncertainties” in the Company’s annual management discussion and analysis for the year ended October 31, 2022 and dated February 28, 2023. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information and forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended.

In connection with the forward-looking information and forward-looking statements contained in this press release, the Company has made certain assumptions. Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this notice.

See also  Titan Medical Reports Fiscal Year 2023 Results

View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005453/en/

logo

Contacts

Kelly Castledine
Tel: 647-660-2560

Leave a Reply

Your email address will not be published. Required fields are marked *